The improved treatment response of NSD1 knockdown was limited to the DNA crosslinking agents cisplatin and carboplatin and was not seen with other types of DNA damaging agents tested: etoposide (topoisomerase II inhibitor), zeocin (radiomimetic), paclitaxel (microtubule inhibitor, also used in head and neck cancer treatment), and mirin (MRE11 inhibitor). Here, NSD1 is linked to head and neck cancer.